First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint.
Tofacitinib inhibits monocyte-derived dendritic cells differentiation in rheumatoid and psoriatic arthritis: a novel mechanism of action
Hospital Professional News Ireland 2020 Oct ;77 (Page 36)
“In this study we investigated the capacity of monocytes to differentiate into dendritic cells in both Rheumatoid (RA) and Psoriatic arthritic patients (PsA). We observed different morphological and functional profiles between monocytes obtained from RA and PsA patients, with RA monocytes primed to differentiate into DC and exhibiting differentiation and activation markers at earlier time point compared to that of PsA. We further demonstrated a novel mechanism of action for Tofacitinib, a JAK/STAT inhibitor recently approved in the treatment of RA and PsA patients. We demonstrated that Tofacitinib inhibits Mo-DC differentiation in both RA and PsA patients, via the regulation of NOX5 expression and ROS production, giving us further insight into the use of the drug as a successful treatment strategy for IA.” -Dr. Viviana Marzaioli
Monocyte-Derived Dendritic Cell Differentiation in Inflammatory Arthritis Is Regulated by the JAK/STAT Axis via NADPH Oxidase Regulation.
miR-17-5p reduces inflammation and bone erosions in collagen induced arthritis mice and directly targets the JAK-STAT pathway in rheumatoid arthritis fibroblast-like synoviocytes
Najm A, Masson FM, Preuss P, Georges S, Ory B, Quillard T, Sood S, Goodyear CS, Veale DJ, Fearon U, Le Goff B, Blanchard F.
Arthritis Rheumatol. 2020 Jul 19.
Rheumatoid arthritis synovial microenvironment induces metabolic and functional adaptations in dendritic cells
Canavan M, Marzaioli V, McGarry T, Bhargava V, Nagpal S, Veale DJ, Fearon U.
Clin Exp Immunol. 2020 Jun 17
Insulin-Resistant Pathways Are Associated With Disease Activity in Rheumatoid Arthritis and Are Subject to Disease Modification Through Metabolic Reprogramming: A Potential Novel Therapeutic Approach
Gallagher L, Cregan S, Biniecka M, Cunningham C, Veale DJ, Kane DJ, Fearon U, Mullan RH.
Arthritis Rheumatol. 2020 Jun
Serum microRNA signature as a diagnostic and therapeutic marker in patients with psoriatic arthritis.
Wade SM, McGarry T, Wade SC, Fearon U, Veale DJ.
J Rheumatol. 2020 Mar 1
Targeting bioenergetics prevents CD4 T cell-mediated activation of synovial fibroblasts in rheumatoid arthritis.
Petrasca A, Phelan JJ, Ansboro S, Veale DJ, Fearon U, Fletcher JM.
Rheumatology (Oxford). 2020 Feb 11
Next-generation analysis of synovial tissue architecture.
Veale DJ, Fearon U.
Nat Rev Rheumatol. 2020 Feb
Enrichment of polyfunctional T cells in PsA synovial tissue. Response to: ‘Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells’ by Raychaudhuri et al.
Canavan M, Wade SM, Veale DJ, Fearon U.
Ann Rheum Dis. 2020 Jan 8
[Epub ahead of print]